focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.76
Ask: 7.50
Change: 1.24 (21.53%)
Spread: 0.74 (10.947%)
Open: 5.72
High: 7.22
Low: 5.72
Prev. Close: 5.76
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

28 Jun 2010 07:00

RNS Number : 2728O
Synairgen plc
28 June 2010
 



Press release

Synairgen plc

('Synairgen' or the 'Company')

Directorate appointment

 

Southampton, UK - 28 June 2010: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence in asthma, COPD and flu, is pleased to announce the appointment of Iain Peter Murray Buchanan to the Board.

Iain Buchanan, aged 57, has joined the Board as a non-executive director with immediate effect. Iain is currently Chief Executive Officer of Novexel SA ('Novexel'), a specialty pharmaceutical company focused on novel anti-infectives. Iain joined Novexel at its formation in 2004 and oversaw its recent sale to AstraZeneca in March 2010. He has some 35 years' commercial experience in the pharmaceutical and biotech industries. He joined Novexel from Vertex Pharmaceuticals (Europe) Limited, where he was Managing Director. Prior to Vertex, Iain was the Regional Licensing Director of Cilag A.G. International, a division of Johnson & Johnson based in Switzerland, where he managed Cilag's international licensee business from 1987 to 1994. Prior to joining Cilag, Iain was Marketing Director at Biogen in Switzerland, with responsibility for business development activities in Europe.

He is also a non-executive director of NOXXON Pharma AG.

Simon Shaw, Chairman of Synairgen, commented, "I am delighted to welcome Iain to the Board. Synairgen will benefit significantly from his extensive business development and licensing experience as we move towards realising the value of our interferon beta programmes in the coming periods."

 

In accordance with the AIM Rules for Companies, the Company confirms that there is no further disclosure obligation required, pursuant to Schedule Two, Paragraph (g).

 

-Ends-

For further information, please contact:

Synairgen plc Tel: + 44 (0) 23 8051 2800

Simon Shaw, Chairman

Richard Marsden, Chief Executive Officer

Matrix Corporate Capital Tel: + 44 (0) 20 3206 7000

Alastair Stratton

Anu Tayal

Threadneedle Communications Tel: + 44 (0) 20 7653 9850

Graham Herring

Josh Royston

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAUVRORRRANUAR
Date   Source Headline
28th Jul 20203:13 pmRNSHolding(s) in Company
28th Jul 20209:01 amRNSHolding(s) in Company
27th Jul 20209:06 amRNSSecond Price Monitoring Extn
27th Jul 20209:00 amRNSPrice Monitoring Extension
23rd Jul 20204:40 pmRNSSecond Price Monitoring Extn
23rd Jul 20204:36 pmRNSPrice Monitoring Extension
22nd Jul 20202:05 pmRNSHolding(s) in Company
21st Jul 20204:15 pmRNSHolding(s) in Company
21st Jul 20207:00 amRNSHolding(s) in Company
21st Jul 20207:00 amRNSClarification Regarding COVID-19 Trial
20th Jul 20204:40 pmRNSSecond Price Monitoring Extn
20th Jul 20204:35 pmRNSPrice Monitoring Extension
20th Jul 202011:05 amRNSSecond Price Monitoring Extn
20th Jul 202011:00 amRNSPrice Monitoring Extension
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
20th Jul 20207:00 amRNSPositive results from trial in COVID-19 patients
15th Jul 20208:00 amRNSHolding(s) in Company
3rd Jul 202012:43 pmRNSHolding(s) in Company
3rd Jul 202012:38 pmRNSHolding(s) in Company
29th Jun 20203:18 pmRNSResult of AGM
22nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20204:36 pmRNSPrice Monitoring Extension
19th Jun 20207:00 amRNSGrant of Options
18th Jun 20207:00 amRNSNational expansion of home-based COVID-19 trial
17th Jun 20204:40 pmRNSSecond Price Monitoring Extn
17th Jun 20204:36 pmRNSPrice Monitoring Extension
12th Jun 20202:01 pmRNSPrice Monitoring Extension
10th Jun 20205:32 pmRNSHoldings in Company
10th Jun 20205:27 pmRNSHoldings in Company
10th Jun 202010:46 amRNSHolding(s) in Company
3rd Jun 20204:21 pmRNSAnnual Report and Notice of Annual General Meeting
28th May 20207:00 amRNSRecruitment of Patients in SG016 Trial Completed
26th May 20207:00 amRNSInitiation of SNG001 in home setting
26th May 20207:00 amRNSPreliminary results for the year ended 31 Dec 2019
11th May 20205:41 pmRNSHolding(s) in Company
6th May 20205:07 pmRNSHolding(s) in Company
5th May 202011:05 amRNSSecond Price Monitoring Extn
5th May 202011:00 amRNSPrice Monitoring Extension
30th Apr 202012:09 pmRNSExtension of clinical study in COVID-19 patients
28th Apr 20205:16 pmRNSHolding(s) in Company
24th Apr 20205:10 pmRNSHolding(s) in Company
16th Apr 20205:35 pmRNSHolding(s) in Company
15th Apr 20201:30 pmRNSHolding(s) in Company
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
14th Apr 202012:00 pmRNSResult of General Meeting
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:00 amRNSPrice Monitoring Extension
14th Apr 20209:00 amRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.